No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
764 |
4. Check minimum number of eventsNone |
764 |
5. Include endpointsNone |
764 |
6. Filter based on genotype QC (FinnGen only) |
679 |
Control definitions (FinnGen only)
- Control exclude
- H7_OCUMUSCLE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- H49
- Name in latin
- Paresis/paralysis nervi oculomotorii
Similar endpoints
↥List of similar endpoints to
Third [oculomotor] nerve palsy
based on the number of shared cases.
Similar with more cases:
- Paralytic strabismus
- Strabismus
- Disorders of ocular muscles, binocular movement, accommodation and refraction
- Diseases of the eye and adnexa
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4483 | 2283 | 2171 |
| Only index persons | 3953 | 2021 | 1932 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.06 | 0.07 | 0.06 |
| Only index persons | 0.07 | 0.07 | 0.07 |
| Median age at first event (years) | |||
| Whole population | 65.73 | 66.58 | 64.73 |
| Only index persons | 64.72 | 65.45 | 63.95 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 679 | 348 | 331 |
| Unadjusted period prevalence (%) | 0.14 | 0.12 | 0.15 |
| Median age at first event (years) | 62.98 | 59.41 | 66.74 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 702
- Matched controls
- 7020
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H49.0
ICD-10 Finland
Third [oculomotor] nerve palsy
+∞
307.7
702
*
H53.2
ICD-10 Finland
Diplopia
48.0
307.7
246
78
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.9
97.3
177
325
D32.02
ICD-10 Finland
Benign tumor of the meninges at the base of the brain
26.0
90.5
64
27
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
+∞
88.4
83
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
11.8
76.5
82
78
AA1AD
NOMESCO Finland
CT of head and brain
4.0
73.8
380
1584
H02.4
ICD-10 Finland
Ptosis of eyelid
9.6
69.8
87
102
XCK00
NOMESCO Finland
Perimetry
6.6
69.2
125
224
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.9
64.0
171
435
I67.1
ICD-10 Finland
Cerebral aneurysm, nonruptured
11.0
55.4
61
60
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.6
51.6
226
812
D32.00
ICD-10 Finland
Benign tumor of the meninges on the outer surface of the cerebrum
13.6
48.1
46
36
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.4
45.7
134
361
H49.1
ICD-10 Finland
Fourth [trochlear] nerve palsy
+∞
38.9
37
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.6
35.4
134
428
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
3.4
33.3
144
500
TAB00
NOMESCO Finland
Lumbar puncture
5.0
32.5
74
161
AAC00
NOMESCO Finland
Ligature of intracranial aneurysm
12.9
31.7
31
25
R51.80
ICD-10 Finland
Headache
3.0
30.0
161
632
PA2BD
NOMESCO Finland
Extensive CT angiography of brain
8.2
28.8
39
50
PA7AD
NOMESCO Finland
CT angiography of head and neck vasculature
5.1
28.6
63
133
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
9.5
25.8
31
34
PA2CC
NOMESCO Finland
Cerebral very extensive angiography with X-ray
26.5
24.2
33
13
G51.0
ICD-10 Finland
Bell palsy
6.3
24.0
41
68
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
7.8
23.5
33
44
A10AB05
ATC
insulin aspart; parenteral
3.4
23.3
92
299
PA6AD
NOMESCO Finland
CT of neck arteries
4.7
23.1
55
124
CE2W4
NOMESCO Finland
Eye movement mapping
124.1
22.7
24
*
H02AB09
ATC
hydrocortisone; systemic
6.3
22.7
39
65
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
18.2
21.5
33
19
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
17.2
21.1
33
20
A10AB01
ATC
insulin (human); parenteral
5.1
21.1
46
96
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
4.7
20.4
48
107
B01AC04
ATC
clopidogrel; oral
2.4
20.3
179
884
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
3.5
19.8
73
226
E10.9
ICD-10 Finland
Type 1 diabetes mellitus, Without complications
4.8
19.7
46
102
A10AA01, ,
ATC
5.9
19.6
36
64
A10AC01
ATC
insulin (human); parenteral
3.1
19.4
87
304
H53.4
ICD-10 Finland
Visual field defects
6.1
19.3
34
58
A10AE04
ATC
insulin glargine; parenteral
2.7
18.3
106
427
PA6BD
NOMESCO Finland
Extensive CT of neck arteries
4.2
18.2
50
126
CEC10
NOMESCO Finland
Recession and resection of extraocular muscle
+∞
17.8
17
*
PA2BC
NOMESCO Finland
Cerebral extensive angiography with X-ray
13.0
17.3
30
24
E10.3
ICD-10 Finland
Type 1 diabetes mellitus, With ophthalmic complications
6.1
17.1
30
51
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
3.2
17.1
71
237
H50.1
ICD-10 Finland
Divergent concomitant strabismus
+∞
16.7
16
*
H3603, E103,
ICD-10 Finland
30.9
16.2
21
7
A10AB04
ATC
insulin lispro; parenteral
4.6
16.1
39
89
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
5.5
16.0
31
58
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
34.2
15.8
20
6
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
2.8
15.7
82
312
H50.2
ICD-10 Finland
Vertical strabismus
163.5
15.5
16
*
A10AA02, ,
ATC
4.2
15.2
42
106
H47.2
ICD-10 Finland
Optic atrophy
32.5
14.9
19
6
CS5Z4
NOMESCO Finland
Specialised imaging for glaucoma
5.0
14.6
32
67
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.1
14.4
178
992
E23.00
ICD-10 Finland
Panhypopituitarism
22.8
14.3
20
9
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.9
14.3
332
2286
CKC12
NOMESCO Finland
Photocoagulation of retina
3.7
14.3
47
135
XCK10
NOMESCO Finland
Photography of fundus of eye
2.5
14.1
96
417
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
16.2
14.0
22
14
H49.9
ICD-10 Finland
Paralytic strabismus, unspecified
+∞
13.6
13
*
103
Kela drug reimbursment
Diabetes, insulin-treated
1.9
13.3
229
1427
N07AA02
ATC
pyridostigmine; systemic
17.1
13.0
20
12
G70.0
ICD-10 Finland
Myasthenia gravis
23.0
12.9
18
8
N03AF02
ATC
oxcarbazepine; oral
4.1
12.8
35
88
H3601, E103,
ICD-10 Finland
17.7
12.6
19
11
N08.39*E11.2
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic nephropathy
5.5
12.4
24
45
D32.9
ICD-10 Finland
Benign neoplasm: Meninges, unspecified
18.4
12.1
18
10
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
21.7
12.1
17
8
N03AX14
ATC
levetiracetam; systemic
4.1
11.9
33
84
H3601, E113,
ICD-10 Finland
5.3
11.8
24
47
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
2.4
11.6
81
355
CS494
NOMESCO Finland
Other visual field testing
4.2
11.5
31
77
CEC30
NOMESCO Finland
Resection of extraocular muscle
+∞
11.5
11
*
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
+∞
11.5
11
*
CEC00
NOMESCO Finland
Recession of extraocular muscle
121.9
11.5
12
*
I63.3
ICD-10 Finland
Cerebral infarction due to thrombosis of cerebral arteries
3.2
11.3
45
146
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.0
11.2
134
731
AAF05
NOMESCO Finland
Ventriculoperitoneal shunt
5.7
11.2
21
38
SPAT1301
SPAT
No procedures
1.8
11.2
234
1533
I60.3
ICD-10 Finland
Subarachnoid haemorrhage from posterior communicating artery
25.5
11.2
15
6
Z3229
NOMESCO Finland
Other healthcare associate professional
2.5
11.1
74
317
I63.5
ICD-10 Finland
Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries
5.4
11.1
22
42
L04AX01
ATC
azathioprine; systemic
3.5
11.1
39
117
H36.00
ICD-10 Finland
Diabetic background retinopathy
5.1
11.1
23
46
H53.1
ICD-10 Finland
Subjective visual disturbances
2.7
10.8
60
235
CS424
NOMESCO Finland
Visual field testing with Goldmann perimetry
10.8
10.8
20
19
D32.0
ICD-10 Finland
Benign neoplasm: Cerebral meninges
21.9
10.7
15
7
B01AC30
ATC
platelet aggregation inhibitors excl. heparin - combinations
2.6
10.7
64
261
215
Kela drug reimbursment
Diabetes, non-insulin-treated
1.8
10.6
198
1250
H36.09*E10.3
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic retinopathy
14.5
10.5
17
12
T90.5
ICD-10 Finland
Sequelae of intracranial injury
7.9
10.5
23
30
S06.3
ICD-10 Finland
Focal brain injury
5.5
10.4
20
37
AAL00
NOMESCO Finland
Endovascular occlusion of intracranial aneurysm
111.6
10.4
11
*
G52.8
ICD-10 Finland
Disorders of other specified cranial nerves
+∞
10.4
10
*
F05
ICPC
Visual disturbance other
3.4
10.4
37
112
ZXD05
NOMESCO Finland
Urgent procedure
1.8
10.3
224
1476
9530/0-C70.0
ICD-O-3
Meningioma, NOS, of cerebral meninges
10.8
10.3
19
18
I60.9
ICD-10 Finland
Subarachnoid haemorrhage, unspecified
4.8
10.3
23
49
H04AA01
ATC
glucagon; nasal, parenteral
5.1
10.1
21
42
AA1BD
NOMESCO Finland
Extensive CT of head and brain
3.9
10.0
29
76
H57.1
ICD-10 Finland
Ocular pain
3.3
9.9
37
116
108
Kela drug reimbursment
Myasthenia gravis
26.4
9.8
13
5
N08.39*E10.2
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic nephropathy
13.6
9.7
16
12
Z49.1
ICD-10 Finland
Extracorporeal dialysis
5.4
9.7
19
36
G35
ICD-10 Finland
Multiple sclerosis
7.3
9.6
22
31
SPAT1229
SPAT
Assessment of need for aid
2.4
9.5
70
314
SPAT1262
SPAT
Handing over of treatment supplies
1.9
9.5
139
810
I69.0
ICD-10 Finland
Sequelae of subarachnoid haemorrhage
7.7
9.5
21
28
H3602, E113,
ICD-10 Finland
30.5
9.4
12
*
XA800
NOMESCO Finland
Neuropsychological investigation
3.1
9.4
39
130
S04.1
ICD-10 Finland
Injury of oculomotor nerve
+∞
9.4
9
*
E10.5
ICD-10 Finland
Type 1 diabetes mellitus, With peripheral circulatory complications
22.0
9.4
13
6
2500B
ICD-9 Finland
Diabetes mellitus without mention of complication[DIABETES MELLITUS SINE COMPLICATIONE ,TYYPPI I]
5.0
9.4
20
41
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
3.0
9.2
42
148
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
13.9
9.2
15
11
E10.00
ICD-10 Finland
Insulin-dependent diabetes diabetic hypoglycemic coma
13.9
9.2
15
11
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.4
9.2
64
280
H36.01
ICD-10 Finland
Diabetic maculopathy
5.1
9.1
19
38
H3603, E113,
ICD-10 Finland
8.5
9.1
19
23
I10
ICD-10 Finland
Essential (primary) hypertension
1.7
9.0
465
3801
E11.00
ICD-10 Finland
Non-insulin dependent diabetes diabetic hypoglycaemic coma
3.1
9.0
37
123
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
1.8
8.9
141
841
205
Kela drug reimbursment
Chronic hypertension
1.7
8.9
216
1459
A10AE05
ATC
insulin detemir; parenteral
2.7
8.8
49
192
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
1.7
8.8
199
1317
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
2.2
8.6
74
355
PA2BG
NOMESCO Finland
MRI examination of vessels in the head with high intensity magnet
11.8
8.6
15
13
N18.8
ICD-10 Finland
Other chronic renal failure
3.9
8.6
25
66
L04AA06
ATC
mycophenolic acid; systemic
4.3
8.5
22
53
A10AD01
ATC
insulin (human); parenteral
4.4
8.5
21
49
R42
ICD-10 Finland
Dizziness and giddiness
1.7
8.4
178
1155
CBJ10
NOMESCO Finland
Fascia plate sling or synthetic material for ptosis correction
91.1
8.4
9
*
H50.31
ICD-10 Finland
Intermittent exotropia
91.1
8.4
9
*
H50.0
ICD-10 Finland
Convergent concomitant strabismus
+∞
8.3
8
*
NHQ40
NOMESCO Finland
Amputation of toe
4.3
8.2
21
50
A28
ICPC
Limited function/disability NOS
1.7
8.2
162
1030
C10AA01
ATC
simvastatin; oral
1.6
8.2
324
2459
E11.3
ICD-10 Finland
Type 2 diabetes mellitus, with ophthalmic complications
3.2
8.2
32
103
H43.1
ICD-10 Finland
Vitreous haemorrhage
3.6
8.2
27
78
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
2.6
8.2
46
182
H36.03
ICD-10 Finland
Proliferative diabetic retinopathy
8.3
8.1
17
21
AAG50
NOMESCO Finland
Stereotactic intracranial radiotherapy
11.9
8.1
14
12
101
Kela drug reimbursment
Anterior pituitary hypofunction
11.9
8.1
14
12
D32.06
ICD-10 Finland
Benign tumor of the meninges os petrosum or clivus area
33.8
8.1
10
*
E22.1
ICD-10 Finland
Hyperprolactinaemia
17.4
8.1
12
7
I60.0
ICD-10 Finland
Subarachnoid haemorrhage from carotid siphon and bifurcation
13.2
7.9
13
10
SPAT1148
SPAT
Treatment of chronic ulcer or burn
1.9
7.8
112
646
ZXC95
NOMESCO Finland
Use of surgical navigator
6.5
7.8
19
30
C08CA01
ATC
amlodipine; oral
1.6
7.7
293
2195
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.6
7.7
354
2771
PA2LT
NOMESCO Finland
Endovascular closure of extensive brain aneurysm
18.6
7.6
11
6
K90
ICPC
Stroke/cerebrovascular accident
3.0
7.6
34
119
CKC10
NOMESCO Finland
Local photocoagulation of retina
4.0
7.5
21
54
XCD10
NOMESCO Finland
Electrophysiological examination of eye
3.4
7.4
26
78
CS434
NOMESCO Finland
Visual field testing with Humphrey automated perimetry
3.4
7.4
26
78
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
9.5
7.3
14
15
SPAT1249
SPAT
Treatment-related counselling outside office
1.6
7.2
260
1919
E11.5
ICD-10 Finland
Type 2 diabetes mellitus, with peripheral circulatory complications
3.3
7.2
26
80
E23.05
ICD-10 Finland
Lack of TSH
30.3
7.2
9
*
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
2.7
7.2
38
146
T89
ICPC
Diabetes insulin dependent
2.8
7.1
35
129
L28
ICPC
Limited function/disability (L)
1.7
7.1
152
985
H47.1
ICD-10 Finland
Papilloedema, unspecified
8.9
7.1
14
16
K91
ICPC
Cerebrovascular disease
4.3
7.0
18
43
TK800
NOMESCO Finland
Hemodialysis
3.6
7.0
23
66
N18
ICPC
Paralysis/weakness
3.6
7.0
23
66
A10AE06
ATC
insulin degludec; parenteral
2.9
7.0
32
113
25000
ICD-8 Finland
Diabetes mellitus, Sine complicatione
3.5
7.0
24
71
H02AB02
ATC
dexamethasone; systemic
1.9
7.0
91
508
A06AD11
ATC
lactulose; oral
1.8
7.0
121
739
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.2
6.9
58
275
109
Kela drug reimbursment
Multiple sclerosis
7.6
6.9
15
20
I60.7
ICD-10 Finland
Subarachnoid haemorrhage from intracranial artery, unspecified
13.9
6.9
11
8
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
8.4
6.8
14
17
E10.2
ICD-10 Finland
Type 1 diabetes mellitus, With renal complications
8.4
6.8
14
17
E10.4
ICD-10 Finland
Type 1 diabetes mellitus, With neurological complications
11.1
6.8
12
11
N08.39
ICD-10 Finland
Glomerular disorders in diabetes mellitus microalbuminuria
9.4
6.8
13
14
PA2YT
NOMESCO Finland
Cerebral artery PTA with stent
16.9
6.8
10
6
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
3.3
6.8
25
78
T90
ICPC
Diabetes non-insulin dependent
1.6
6.8
183
1259
CKC15
NOMESCO Finland
Panretinal photocoagulation
7.3
6.7
15
21
C03CA01
ATC
furosemide; systemic
1.5
6.6
244
1803
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
2.3
6.6
48
215
8000/0-C70.0
ICD-O-3
Neoplasm, benign of cerebral meninges
10.1
6.6
12
12
NHQ30
NOMESCO Finland
Amputation of foot, transmetatarsal
10.1
6.6
12
12
CKD05
NOMESCO Finland
Puncture of vitreous body with injection of medication
2.3
6.4
48
217
N28
ICPC
Limited function/disability (N)
3.5
6.3
21
61
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
1.6
6.3
192
1355
C09AA02
ATC
enalapril; systemic
1.6
6.3
145
957
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
2.0
6.3
69
364
H49.4
ICD-10 Finland
Progressive external ophthalmoplegia
+∞
6.3
6
*
SPAT1312
SPAT
General health counselling
1.6
6.3
201
1436
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
5.8
6.2
16
28
A10BA02
ATC
metformin; oral
1.5
6.2
214
1555
H3600, E103,
ICD-10 Finland
7.8
6.1
13
17
N02BE01
ATC
paracetamol; systemic, rectal
1.8
6.1
615
5599
AAF00
NOMESCO Finland
Ventriculostomy
10.1
6.0
11
11
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
1.7
6.0
122
777
AA1BM
NOMESCO Finland
MRI examination of brain with 3 Tesla magnet
6.1
6.0
15
25
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
57
41
15.04
62.83
1.1
1.1
4.22
1.19
nmol/l
—
14
6
93
145
7.24
58.51
1.4
1.4
1064.61
885.89
e6/l
0.07
71
112
58
49
12.81
58.14
1.1
1.1
—
—
—
0
0
91
143
7.16
56.80
1.4
1.3
14.79
15.71
e6/l
0.04
67
107
44
35
13.35
45.58
1.0
1.0
1.18
1.14
u/l
0.12
18
18
45
41
11.66
42.81
1.0
1.0
—
—
—
0
0
47
48
10.42
41.38
1.1
1.2
50.34
43.33
mg/l
0.26
40
41
381
2064
2.85
40.60
2.6
2.2
143.68
273.13
u/l
2.57
364
1965
43
46
9.89
36.57
1.0
1.1
359.46
253.80
mg/l
1.31
37
41
226
1050
2.70
30.75
2.0
2.2
28.71
29.46
s
1.53
215
1016
35
40
9.16
28.26
1.1
1.1
0.51
0.51
ratio
—
9
23
40
62
6.78
24.97
1.4
1.2
—
—
—
0
0
106
369
3.21
24.00
1.3
1.4
63.33
50.75
au/ml
—
6
30
110
409
3.00
22.17
2.5
2.6
17.13
18.59
au/ml
0.10
11
37
27
31
9.02
21.66
1.2
1.1
—
—
—
0
0
504
3748
2.22
19.88
8.8
5.3
7.16
6.75
mmol/l
3.76
488
3581
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
25
32
8.06
18.39
1.1
1.2
—
—
—
0
0
75
267
3.03
16.17
1.8
2.2
33.94
39.53
u/l
1.73
63
236
407
2925
1.93
15.91
7.3
5.3
34.55
35.32
g/l
1.91
393
2733
157
811
2.21
15.58
10.7
7.7
1.15
1.08
mmol/l
0.08
134
678
158
827
2.17
15.13
10.7
7.7
5.05
5.13
kpa
0.51
152
800
158
828
2.17
15.08
10.7
7.6
12.77
11.97
kpa
0.98
152
804
114
529
2.38
14.51
2.3
2.8
9.77
10.95
g/l
2.36
105
489
422
3138
1.86
14.11
16.4
16.1
1.23
1.28
inr
1.39
364
2623
23
38
6.22
13.47
1.3
2.6
—
—
—
0
0
121
603
2.22
12.95
1.9
3.3
66.41
66.42
g/l
0.01
110
563
18
9
20.48
12.50
1.1
1.1
—
—
—
0
0
161
913
1.99
12.19
2.0
1.9
—
—
—
0
0
122
633
2.12
11.73
3.4
2.1
353.92
380.24
nmol/l
0.85
114
594
135
743
2.01
11.04
11.5
7.9
96.10
95.22
%
1.12
130
724
21
22
9.80
10.81
1.1
1.3
—
—
—
0
0
194
1212
1.83
10.79
2.1
2.0
—
—
—
0
0
427
3331
1.72
10.74
12.8
7.5
1.21
1.21
mmol/l
0.29
365
2891
149
859
1.93
10.63
2.1
1.9
—
—
—
0
0
158
932
1.90
10.51
11.1
6.0
1.09
1.04
mmol/l
1.28
152
861
27
65
4.28
10.44
1.0
1.1
—
—
—
0
0
237
1597
1.73
10.07
5.7
4.4
92.63
88.24
%
2.01
230
1562
390
3001
1.67
10.03
12.3
6.9
1.20
1.21
mmol/l
1.72
367
2775
340
2544
1.65
9.60
5.3
4.1
64.36
58.91
ng/l
0.06
282
1929
429
3417
1.66
9.37
7.7
7.0
11.12
12.05
umol/l
0.90
410
3273
220
1508
1.67
8.51
4.0
2.8
4.81
5.70
e6/l
0.58
199
1378
176
1142
1.72
8.33
3.8
3.5
0.83
0.81
mmol/l
0.96
168
1085
113
643
1.90
8.26
13.1
7.2
10.91
10.51
mmol/l
0.23
113
608
409
3279
1.59
8.19
5.6
4.2
14.12
4.88
estimate
0.28
94
718
527
4499
1.69
8.12
5.4
4.5
14.68
12.97
mm/h
1.59
497
4174
17
22
7.89
7.91
1.0
1.1
—
—
—
0
0
11
6
18.59
7.62
1.1
1.7
—
—
—
0
0
13
11
12.01
7.60
1.2
1.2
—
—
—
0
0
14
14
10.18
7.56
1.1
1.3
—
—
—
0
0
256
1866
1.59
7.54
5.9
4.2
0.00
0.00
estimate
0.50
84
641
366
2893
1.55
7.54
3.6
2.9
—
—
estimate
—
0
0
18
41
4.48
7.46
1.6
2.0
—
—
—
0
0
272
2025
1.56
7.24
3.3
2.7
53.86
61.25
u/l
1.29
256
1896
17
26
6.67
7.14
1.2
1.2
—
—
—
0
0
399
3245
1.53
7.01
5.5
4.2
0.01
0.00
estimate
0.49
91
702
16
24
6.79
6.84
2.9
2.8
593.50
1350.00
u/ml
0.79
16
24
537
4686
1.62
6.74
11.1
8.7
85.11
80.35
u/l
0.94
508
4430
426
3531
1.53
6.72
11.7
9.9
4.40
4.18
e9/l
1.28
387
3097
271
2047
1.53
6.61
3.8
3.4
32.11
34.00
u/l
0.36
254
1932
46
202
2.37
6.59
1.1
1.4
0.25
0.24
g/l
0.58
46
193
206
1465
1.57
6.59
6.3
4.4
1.02
1.02
kg/l
0.14
147
993
47
209
2.34
6.55
1.1
1.4
1.23
1.18
g/l
0.59
47
200
172
1176
1.61
6.48
1.7
1.7
1267.64
1195.42
nmol/l
0.35
130
894
479
4089
1.54
6.45
6.9
5.0
209.57
2749.24
e6/l
1.87
14
75
37
149
2.57
6.37
1.5
1.8
4.87
46.42
iu/l
0.48
12
55
401
3308
1.49
6.28
5.7
4.2
0.03
0.46
estimate
0.47
88
672
14
20
7.12
6.24
1.1
1.1
—
—
—
0
0
14
20
7.12
6.24
1.1
1.1
—
—
—
0
0
115
715
1.73
6.22
5.7
4.0
2.25
1.85
mmol/l
0.55
101
611
314
2473
1.49
6.14
5.6
4.2
0.06
0.04
estimate
0.18
71
588
35
141
2.56
6.03
2.1
1.4
6.04
9.72
u/l
1.56
25
106
60
307
2.04
5.94
2.0
1.8
2.60
2.33
ug/l
0.07
53
273
44
201
2.27
5.79
1.7
1.5
0.34
0.11
iu/ml
0.40
11
32
22
70
3.21
5.78
1.6
2.0
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
47
221
2.21
5.77
3.0
3.2
0.29
0.36
iu/ml
1.01
28
124
216
1593
1.51
5.74
3.2
2.6
—
—
—
0
0
23
76
3.09
5.69
1.6
1.9
—
—
—
0
0
9
7
13.00
5.59
1.1
1.4
—
—
—
0
0
344
2793
1.45
5.59
3.0
2.5
74.90
78.11
nmol/l
1.32
313
2493
13
21
6.29
5.40
1.1
1.2
—
—
—
0
0
22
74
3.04
5.30
1.3
1.1
3.58
1.68
u/ml
0.75
12
25
592
5393
1.62
5.16
6.1
5.3
1.93
1.97
mu/l
0.22
552
4941
31
129
2.47
5.03
7.0
7.2
103.96
105.08
mmol/l
0.57
26
118
86
529
1.71
4.82
6.0
4.2
139.01
87.55
ng/l
1.18
81
466
272
2157
1.43
4.81
4.8
3.7
59.25
81.56
e6/l
0.24
223
1657
13
25
5.28
4.78
1.0
1.0
1656.31
1576.80
miu/ml
0.06
13
25
38
179
2.19
4.68
1.5
1.6
—
—
—
0
0
28
117
2.45
4.53
2.1
1.5
142.11
163.59
au/ml
—
9
38
8
8
10.10
4.53
1.1
1.5
—
—
—
0
0
510
4548
1.44
4.45
5.3
4.2
14.85
14.88
pmol/l
0.11
477
4152
94
605
1.64
4.45
2.6
2.4
4.55
7.07
ug/l
1.72
83
533
277
2231
1.40
4.38
4.4
3.5
6.97
7.57
mmol/l
1.55
233
1871
222
1723
1.42
4.34
2.8
2.4
2.99
3.01
mg/l
0.04
198
1478
637
5966
1.73
4.34
34.7
21.6
139.41
139.62
mmol/l
1.07
630
5854
186
1398
1.45
4.32
1.9
1.8
468.77
20583630.54
pmol/l
0.99
159
1166
26
108
2.46
4.27
1.4
2.2
3.90
4.60
mmol/24h
0.42
20
96
637
5972
1.72
4.24
35.2
21.8
4.00
3.99
mmol/l
0.13
630
5852
174
1299
1.45
4.18
5.2
4.3
367.31
382.00
ng/l
0.03
144
1071
36
175
2.11
4.13
1.5
1.6
—
—
—
0
0
46
245
1.94
4.12
1.5
1.8
3.85
8.90
iu/ml
1.19
11
60
235
1858
1.40
4.09
4.0
3.5
0.43
0.50
e6/l
0.23
185
1365
282
2301
1.38
4.05
3.8
3.6
2.36
2.35
mmol/l
0.37
254
2074
20
75
2.72
4.02
1.3
1.1
5.50
6.68
u/ml
—
8
31
99
662
1.58
4.01
4.5
3.6
—
—
—
0
0
55
315
1.81
3.96
5.5
4.8
1.53
1.53
%
0.01
49
300
42
220
1.97
3.96
1.7
2.8
0.00
0.00
g/l
-0.00
34
193
19
70
2.76
3.95
1.1
1.1
—
—
—
0
0
620
5797
1.60
3.87
28.5
17.9
24.04
25.77
mg/l
0.75
553
4843
37
187
2.03
3.85
2.0
1.6
—
—
—
0
0
39
201
2.00
3.85
2.1
1.4
24.03
29.02
iu/l
0.33
32
165
59
349
1.75
3.82
1.5
1.5
—
—
—
0
0
10
20
5.06
3.70
1.1
1.2
—
—
—
0
0
46
257
1.85
3.60
1.8
3.0
0.66
1.16
g/l
0.76
41
228
245
1987
1.36
3.55
1.8
1.8
20.39
19.99
nmol/l
0.14
216
1672
267
2202
1.34
3.45
5.6
4.2
17.37
9.13
mg/mmol
1.51
182
1388
209
1664
1.36
3.38
4.2
2.9
345.22
350.58
umol/l
0.29
192
1459
28
134
2.13
3.38
1.2
1.3
—
—
—
0
0
28
134
2.13
3.38
1.4
1.3
—
—
—
0
0
44
248
1.83
3.36
2.0
4.4
54.35
77.18
mg/l
0.41
39
210
41
226
1.86
3.36
1.7
4.2
2.56
2.69
ratio
0.05
29
130
433
3846
1.33
3.27
4.1
3.5
59.66
52.91
u/l
0.56
405
3614
6
7
8.63
3.27
1.2
1.4
—
—
—
0
0
6
7
8.63
3.27
1.2
1.0
—
—
—
0
0
9
19
4.78
3.24
1.2
1.0
—
—
—
0
0
42
237
1.82
3.21
1.5
1.3
—
—
—
0
0
104
741
1.47
3.15
9.7
7.6
—
—
—
0
0
24
112
2.18
3.09
1.6
1.8
—
—
—
0
0
264
2203
1.32
3.06
3.6
3.3
1627.68
1522.55
ng/l
0.13
234
1907
26
126
2.10
3.06
1.3
1.3
—
—
—
0
0
26
126
2.10
3.06
1.3
1.3
—
—
—
0
0
14
51
2.78
3.00
1.1
1.1
102.21
98.33
%
0.32
14
46
31
163
1.94
2.94
2.6
3.7
31.15
34.56
umol/l
0.29
26
143
30
156
1.96
2.94
1.3
1.5
—
—
—
0
0
336
2912
1.30
2.90
2.3
2.2
93.23
94.56
pmol/l
0.20
175
1544
602
5668
1.44
2.85
6.2
5.4
6.34
6.02
mmol/l
4.93
557
5166
27
138
1.99
2.78
9.5
6.6
3233.56
332.32
iu/ml
—
9
22
17
72
2.39
2.74
1.2
1.4
—
—
—
0
0
643
6143
1.56
2.72
35.6
23.6
85.75
80.08
umol/l
1.93
638
6070
68
458
1.54
2.70
1.7
1.8
—
—
—
0
0
28
500
0.54
2.65
1.7
2.0
3.61
3.47
ratio
0.21
17
409
31
170
1.86
2.63
1.4
1.3
23.88
5.27
u/ml
—
5
27
7
15
4.70
2.60
1.0
1.1
—
—
—
0
0
8
20
4.03
2.57
1.1
1.1
—
—
—
0
0
41
247
1.70
2.56
3.5
3.2
—
—
—
0
0
18
81
2.25
2.56
1.2
1.5
—
—
—
0
0
12
44
2.76
2.55
1.3
1.6
—
—
—
0
0
25
129
1.97
2.53
1.4
1.4
240.47
278.17
u/ml
0.31
19
75
24
122
2.00
2.53
1.5
1.6
—
—
—
0
0
5
8
6.28
2.37
4.8
7.5
5.14
5.63
mmol/l
—
5
8
586
5535
1.36
2.34
9.3
6.8
43.07
39.75
mmol/mol
9.54
548
5172
635
6084
1.46
2.28
17.1
12.8
25.86
25.76
u/l
0.05
616
5913
72
511
1.46
2.25
1.8
1.7
—
—
—
0
0
73
520
1.45
2.24
2.8
3.0
61.51
63.77
ml/min/173m2
0.24
41
227
146
1168
1.32
2.22
3.2
3.2
0.93
0.95
e6/l
0.03
87
636
20
372
0.52
2.20
1.5
1.7
3.26
3.52
mmol/l
—
10
275
371
3326
1.24
2.19
3.0
2.8
—
—
—
0
0
74
532
1.44
2.17
7.2
3.7
1.23
1.23
mmol/l
0.01
66
463
50
332
1.54
2.15
1.9
1.9
1.61
1.45
g/l
0.51
41
301
73
525
1.44
2.14
3.9
3.3
237.71
238.08
ng/l
0.00
64
485
142
1140
1.31
2.10
4.5
2.7
11.75
12.60
umol/l
0.87
132
1063
19
96
2.01
2.07
1.2
1.1
81.80
15.33
iu/ml
—
5
18
26
147
1.80
2.05
1.5
1.5
—
—
—
0
0
0
58
0.00
2.04
0.0
1.6
—
0.96
—
0
36
0
58
0.00
2.04
0.0
1.6
—
1.17
—
0
36
0
58
0.00
2.04
0.0
1.6
—
1.00
—
0
36
15
70
2.17
1.99
1.2
1.2
—
—
—
0
0
125
995
1.31
1.97
4.7
2.7
20.13
22.37
%
1.20
116
932
16
78
2.08
1.92
1.3
1.6
—
—
—
0
0
30
182
1.68
1.88
1.8
1.6
—
—
—
0
0
87
661
1.36
1.88
2.6
2.5
0.21
0.21
g/l
0.25
81
619
147
1204
1.28
1.87
1.5
1.5
3.12
2.58
g/l
0.55
100
737
315
2809
1.22
1.86
4.2
3.1
146.50
137.78
ug/l
0.24
293
2602
18
94
1.94
1.81
1.5
1.7
—
—
—
0
0
27
163
1.68
1.74
3.1
3.0
189.41
196.67
%
0.21
27
157
30
187
1.63
1.72
3.8
3.0
3.35
3.61
g/l
0.43
30
181
584
5579
1.28
1.66
25.1
17.4
76.52
77.51
ml/min/173m2
0.48
558
5224
103
819
1.30
1.65
6.4
4.4
260.13
258.95
u/l
0.02
97
775
37
246
1.53
1.63
1.7
1.8
—
—
—
0
0
17
92
1.87
1.57
8.9
5.6
11.18
11.76
mg/l
0.28
17
87
644
6246
1.38
1.54
41.4
27.0
252.56
245.97
e9/l
1.71
636
6132
644
6246
1.38
1.54
41.2
26.9
90.84
91.47
fl
3.07
639
6175
8
33
2.44
1.54
1.0
1.0
—
—
—
0
0
644
6248
1.37
1.52
41.3
27.0
4.40
4.44
e12/l
1.27
634
6113
644
6248
1.37
1.52
42.5
27.5
39.39
39.98
%
2.02
639
6172
570
5445
1.25
1.52
5.2
4.5
1.39
1.28
mmol/l
2.30
522
4955
644
6250
1.37
1.50
41.6
27.2
131.48
134.02
g/l
3.91
639
6175
128
1060
1.25
1.49
4.6
2.7
2.19
2.26
g/l
0.75
118
986
9
37
2.45
1.48
1.4
1.4
—
—
—
0
0
15
80
1.89
1.45
1.1
1.5
—
—
—
0
0
57
424
1.37
1.44
4.1
3.9
2.15
1.97
mmol/l
0.14
40
315
162
1382
1.22
1.44
3.0
2.9
2.46
2.46
mmol/l
0.15
148
1230
7
29
2.43
1.39
1.1
1.1
—
—
—
0
0
94
762
1.27
1.32
3.4
3.1
6.17
8.92
umol/l
1.60
84
687
10
48
2.10
1.28
1.2
1.2
—
—
—
0
0
10
48
2.10
1.28
1.0
1.1
—
—
—
0
0
6
25
2.41
1.24
1.0
1.1
—
—
—
0
0
13
70
1.87
1.24
2.8
2.6
—
—
—
0
0
25
164
1.54
1.22
3.2
2.6
197.47
103.81
ug/min
0.52
15
91
49
367
1.36
1.21
1.4
1.2
245.91
147.63
u/ml
0.63
20
142
271
2457
1.17
1.20
2.2
2.0
1.35
1.32
mmol/l
0.25
233
2031
6
26
2.32
1.19
1.0
1.0
—
—
—
0
0
10
50
2.01
1.17
1.0
1.1
—
—
—
0
0
10
50
2.01
1.17
1.0
1.1
—
—
—
0
0
245
2209
1.17
1.16
5.9
5.8
8.62
2.63
ug/l
0.45
220
1971
29
199
1.48
1.16
4.2
3.3
8.74
8.23
kpa
0.46
29
194
196
1744
1.17
1.09
4.9
3.6
3.55
0.06
estimate
0.49
71
557
7
33
2.13
1.05
1.7
1.1
211.00
687.54
u/l
—
7
28
5
22
2.28
1.03
1.0
1.2
—
—
—
0
0
7
34
2.07
1.03
1.0
1.4
1.00
3.22
u/field
—
7
23
21
139
1.53
1.01
1.6
1.4
—
—
—
0
0
12
68
1.78
1.01
1.3
1.6
—
—
—
0
0
9
49
1.85
0.99
1.0
1.1
—
—
—
0
0
0
29
0.00
0.98
0.0
1.2
—
—
—
0
0
7
36
1.95
0.97
1.4
1.4
—
—
—
0
0
7
36
1.95
0.97
1.4
1.4
—
—
—
0
0
494
4725
1.15
0.97
34.8
22.2
14.01
13.76
%
3.25
489
4673
588
5702
1.19
0.96
6.3
5.3
4.34
4.55
mmol/l
5.28
546
5275
6
27
2.23
0.93
1.5
2.2
—
88860.80
—
0
5
10
55
1.83
0.92
1.0
1.1
—
—
—
0
0
6
28
2.15
0.91
1.0
1.1
—
—
—
0
0
584
5666
1.18
0.91
6.2
5.2
1.39
1.46
mmol/l
3.48
540
5200
62
504
1.25
0.90
2.8
2.5
10.56
13.12
nmol/l
1.69
56
450
6
30
2.01
0.87
1.3
1.7
—
—
—
0
0
6
31
1.94
0.84
1.3
1.6
—
—
—
0
0
24
171
1.42
0.84
5.3
3.4
1.44
1.88
index
—
9
102
35
268
1.32
0.81
2.2
2.0
—
—
—
0
0
9
148
0.60
0.79
1.0
1.2
1.54
1.56
g/l
—
9
148
13
82
1.60
0.78
1.3
1.0
—
—
—
0
0
596
5810
1.17
0.78
7.2
6.1
2.47
2.63
mmol/l
4.41
555
5346
6
34
1.77
0.76
1.2
1.5
69.77
55.02
ug/l
—
6
34
6
34
1.77
0.76
1.3
1.6
—
—
—
0
0
5
25
2.01
0.73
4.2
2.4
0.65
0.61
mmol/l
—
5
25
7
39
1.80
0.72
6.3
3.2
0.57
0.95
%
—
7
39
7
41
1.71
0.70
4.7
1.9
—
—
—
0
0
194
1780
1.12
0.69
4.9
4.7
21.22
21.25
%
0.01
107
900
7
43
1.63
0.67
1.4
1.3
—
—
—
0
0
5
28
1.79
0.66
1.4
1.3
—
—
—
0
0
10
63
1.60
0.62
1.0
1.1
—
—
—
0
0
5
30
1.67
0.61
3.2
2.0
—
—
—
0
0
5
30
1.67
0.61
3.2
2.0
—
—
—
0
0
16
114
1.41
0.59
2.7
2.2
196.17
6193.43
u/l
—
6
35
120
1082
1.13
0.58
3.3
3.4
5.20
2.05
e6/l
0.89
58
552
6
36
1.67
0.56
3.3
3.4
84.50
104.22
%
—
6
36
15
206
0.72
0.56
1.6
1.6
63.17
11.66
u/ml
—
6
39
70
609
1.17
0.56
3.1
2.4
71.79
34.23
u/l
0.66
56
503
22
168
1.32
0.55
1.7
1.3
—
—
—
0
0
12
82
1.47
0.54
2.7
3.8
—
—
—
0
0
6
40
1.50
0.51
3.3
2.4
202.12
115.49
ng/l
—
6
40
6
40
1.50
0.51
2.8
2.5
—
—
—
0
0
21
267
0.78
0.48
1.3
1.3
—
—
—
0
0
7
48
1.46
0.47
1.0
1.2
—
—
—
0
0
10
142
0.70
0.46
1.0
1.1
—
7.43
—
0
15
23
183
1.27
0.45
2.0
1.8
39.00
42.21
nmol/l
0.35
23
174
20
157
1.28
0.44
1.2
1.3
—
—
—
0
0
5
31
1.62
0.43
2.0
4.9
—
—
—
0
0
5
31
1.62
0.43
3.2
2.0
—
—
—
0
0
14
105
1.34
0.41
1.1
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
121
1117
1.10
0.41
1.3
1.3
26.71
34.84
iu/ml
0.38
25
348
0
17
0.00
0.40
0.0
2.0
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
13
97
1.35
0.39
1.1
1.1
—
—
—
0
0
148
1385
1.09
0.38
1.8
1.8
1.32
1.35
mg/l
0.05
115
1092
22
268
0.82
0.38
1.0
1.0
—
—
—
0
0
12
158
0.76
0.37
1.4
1.2
0.85
0.91
g/l
0.36
12
158
16
125
1.29
0.37
1.7
1.5
—
—
—
0
0
21
171
1.24
0.36
1.5
1.4
—
—
—
0
0
18
144
1.26
0.35
1.9
1.9
155.67
219.74
pmol/l
1.87
18
133
6
43
1.40
0.35
1.3
1.3
—
—
—
0
0
14
178
0.78
0.34
1.1
1.1
—
—
—
0
0
14
177
0.79
0.33
1.1
1.1
—
—
—
0
0
6
47
1.28
0.32
1.0
1.3
—
—
—
0
0
21
250
0.84
0.30
1.9
1.7
0.26
0.34
mg/l
0.41
11
117
9
72
1.25
0.25
2.2
1.7
—
—
—
0
0
9
72
1.25
0.25
2.2
1.7
—
—
—
0
0
9
72
1.25
0.25
2.2
1.7
—
—
—
0
0
75
807
0.92
0.25
5.8
5.0
32.40
32.20
%
0.06
60
522
58
630
0.91
0.24
1.6
1.7
1.50
1.51
%
0.02
48
544
140
1334
1.06
0.24
1.3
1.3
1.03
1.65
u/ml
0.72
35
355
17
143
1.19
0.23
1.5
1.6
—
—
—
0
0
78
729
1.08
0.23
3.2
4.3
10.30
28.19
ug/l
0.83
67
608
5
40
1.25
0.22
3.2
1.8
—
—
—
0
0
5
40
1.25
0.22
3.2
1.9
—
—
—
0
0
5
40
1.25
0.22
3.2
1.9
—
—
—
0
0
5
40
1.25
0.22
3.2
1.8
—
—
—
0
0
20
172
1.17
0.22
1.9
2.1
—
—
—
0
0
78
731
1.08
0.22
1.4
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
0.07
—
0
5
0
10
0.00
0.21
0.0
3.0
—
76.60
—
0
10
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
8
103
0.77
0.21
1.3
1.6
1368.33
915.42
mu/l
—
8
88
6
48
1.25
0.20
1.0
1.3
—
—
—
0
0
107
1020
1.06
0.19
1.3
1.3
3.65
11.64
u/ml
1.71
40
378
40
433
0.92
0.17
1.8
2.1
—
—
—
0
0
23
206
1.12
0.16
1.9
2.2
—
—
—
0
0
95
908
1.05
0.16
1.4
1.5
—
—
—
0
0
20
178
1.13
0.15
1.5
1.3
—
—
—
0
0
9
83
1.09
0.14
1.1
1.1
1.53
1.51
g/l
—
9
76
9
83
1.09
0.14
1.0
1.4
—
—
—
0
0
5
44
1.14
0.10
1.0
1.7
—
—
—
0
0
18
197
0.91
0.10
1.6
1.4
246.91
300.88
ug/g
0.65
11
116
5
46
1.09
0.09
1.2
1.7
—
—
—
0
0
5
62
0.81
0.08
1.2
2.3
1.60
1.97
u/field
—
5
34
10
88
1.14
0.08
1.0
1.4
—
—
—
0
0
8
76
1.05
0.07
3.5
1.5
0.79
24.91
nmol/l
—
8
70
9
88
1.02
0.07
1.0
1.4
—
—
—
0
0
40
385
1.04
0.06
1.7
2.0
—
—
—
0
0
29
282
1.03
0.02
3.0
3.5
24.96
4966.45
u/ml
0.80
23
246
19
183
1.04
0.01
1.5
1.6
—
—
—
0
0
20
193
1.04
0.01
2.0
1.9
4.47
4.13
mg/l
0.06
15
149
15
144
1.04
0.00
6.5
4.2
26.12
28.20
mg/l
—
9
100
17
176
0.97
0.00
1.5
1.6
17266.27
17129.93
e6/l
0.00
11
130
49
494
0.99
0.00
1.4
1.5
—
—
—
0
0
20
198
1.01
0.00
1.2
1.3
—
—
—
0
0
132
1317
1.00
0.00
3.0
3.3
0.68
0.77
ug/l
0.93
100
887
8
84
0.95
-0.00
1.0
1.4
—
—
—
0
0
8
83
0.96
-0.00
1.0
1.4
—
—
—
0
0
5
52
0.96
-0.00
1.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
8
86
0.93
-0.00
1.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
52.00
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_PARASTRA3 and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_PARASTRA3 | 1.566 [1.37, 1.79] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.183 |
During the follow-up period (1.1.1998 — 31.12.2019), 692 out of 1999 females with H7_PARASTRA3 died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_PARASTRA3 | 1.569 [1.36, 1.81] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.022 |
During the follow-up period (1.1.1998 — 31.12.2019), 689 out of 1924 males with H7_PARASTRA3 died.
Mortality risk
Mortality risk for people of age
years, who have H7_PARASTRA3.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.185% | 0.384% |
| 5 | 0.985% | 1.951% |
| 10 | 2.446% | 4.668% |
| 15 | 4.765% | 8.998% |
| 20 | 8.383% | 15.595% |
Relationships between endpoints
↥Index endpoint: H7_PARASTRA3 – Third [oculomotor] nerve palsy
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data